Introduction {#tca12946-sec-0005}
============

Lung cancer is the leading cause of cancer death worldwide.[1](#tca12946-bib-0001){ref-type="ref"} In the United States, the age‐adjusted mortality rate of lung cancer is 40.6 per 100 000 people, which is double the age‐adjusted mortality of breast cancer at 20.3 per 100 000 people.[2](#tca12946-bib-0002){ref-type="ref"} Recent technological and medical improvements have contributed to longer life expectancy. However, the prevalence of chronic disease and cancer has increased with the global aging of the population. The initial cancer stage at the time of diagnosis usually determines survival prospects. However, the presence of a diversity of comorbidities will influence treatment planning and the effectiveness of such treatment.

Chronic kidney disease (CKD) markers account for 4.4% of overall cancer incidence and are responsible for 3.3 years of life lost.[3](#tca12946-bib-0003){ref-type="ref"} However, studies of survival outcomes of lung cancer patients with deteriorated renal function have shown conflicting results in the literature.[4](#tca12946-bib-0004){ref-type="ref"}, [5](#tca12946-bib-0005){ref-type="ref"}, [6](#tca12946-bib-0006){ref-type="ref"}, [7](#tca12946-bib-0007){ref-type="ref"}, [8](#tca12946-bib-0008){ref-type="ref"} In this study, we first evaluated survival outcomes of patients with lung cancer and coexisting CKD using a propensity‐matched study using two commonly used formulas for estimating glomerular filtration rate. Second, we tested the hypothesis that CKD is an independent risk factor for mortality in patients with lung cancer.

Methods {#tca12946-sec-0006}
=======

We collected clinical data from three hospitals from the Chang Gung Medical Foundation (Kaohsiung Chang Gung Hospital, Chang Gung Memorial Hospital at Keelung, and Chang Gung Memorial Hospital at Chiayi). We included all adult patients (aged \> 18 years) diagnosed with lung cancer from January 2007 to December 2012 in this retrospective study. Propensity score matching was used, with a 1:1 match of patients with lung cancer and coexisting CKD to patients with lung cancer without CKD based on age, gender, smoking status, comorbidity score, histology, and lung cancer stage. The creatinine level measured at the time of cancer diagnosis or clinical staging workup was used to calculate the estimated glomerular filtration rate (eGFR). An eGFR \< 60 mL/minute/1.73 m^2^ in the presence of proteinuria/hematuria or the presence of abnormal kidney imaging was used to define CKD; otherwise the sole presence of a creatinine eGFR \< 60 mL/min/1.73 m^2^ was considered non‐CKD. CKD was staged according to current international guidelines.[9](#tca12946-bib-0009){ref-type="ref"}

We used two different formulas to estimate GFR: the Cockcroft--Gault formula (CKD‐CG)[10](#tca12946-bib-0010){ref-type="ref"} and the Chronic Kidney Disease Epidemiology Collaboration formula (CKD‐EPI).[11](#tca12946-bib-0011){ref-type="ref"} Electronic medical records and cancer center databases at the respective hospitals were cross‐matched to determine the coexistence of lung cancer and CKD. Clinical data extracted from the medical records included: age at diagnosis of lung cancer, gender, smoking history, creatinine level, cancer histology and stage at diagnosis, primary treatment received (all treatment modes administered within 3 months after diagnosis), Charlson comorbidity index (CCI)[12](#tca12946-bib-0012){ref-type="ref"} and overall survival. The 19 chronic disease morbidity scores were added to calculate the CCI, which was used to determine an association between CKD and mortality. Lung cancer was staged according to the 7th edition of the tumor node metastasis (TNM) staging system for lung cancer.[13](#tca12946-bib-0013){ref-type="ref"} We excluded cases with incomplete medical records, incomplete cancer staging, or the absence of lung cancer pathology reports reconfirmed by our in‐house pathologist. Overall survival (OS) was measured from the day of pathology confirmation to the last follow‐up or at the end of 2015, whichever came first. Patients lost to follow‐up were contacted by telephone by the cancer center case manager, and those not reachable by telephone were presumed dead if they had withdrawn from National Health Insurance. National Health Insurance offers universal coverage to \> 99% of the Taiwanese population. Patients are excluded from the scheme as a result of death, missing premium payments for \> 6 months, emigration, or change of nationality. The Health Promotion Administration, Ministry of Health and Welfare, Taiwan, release an annual death report of all cancer cases registered back to each cancer center for a status update. The institutional review board of Chang Gung Memorial Hospital approved this study.

Statistical analysis {#tca12946-sec-0007}
--------------------

The propensity score was calculated using logistic regression with CKD as the dependent variable. Propensity matching was used to select control patients (CKD) who were similar to patients without CKD based on CKD‐CG and CKD‐EPI formulas. The matching process included several factors simultaneously (age, gender, smoking status, CCI score, lung cancer clinical staging, lung cancer history, and primary treatment).[14](#tca12946-bib-0014){ref-type="ref"} For matched pairing, we used a caliper width of 0.2 x the standard deviation of the propensity score without replacement.[15](#tca12946-bib-0015){ref-type="ref"}

Comparisons of clinicopathological parameters among different groups were made using chi‐square or Fisher\'s exact tests for categorical variables and analysis of variance for numerical variables. Continuous variables were categorized into a categorical variable using median values as the cutoff point. We divided clinical stage into stage I--IIIA versus IIIB--IV, and treatment modality into supportive treatment, surgical treatment (excluding diagnostic/staging procedure), and medical treatment groups. OS was assessed using the Kaplan--Meier method, and differences in survival were calculated using the log‐rank test. Cox proportional hazard analysis was used to estimate the level of significance and the relative risks with 95% confidence intervals (CIs). A *P* value \< 0.05 was considered significant. The clinical data were analyzed using SPSS version 22.0 (IBM Corp., Armonk, NY, USA).

Results {#tca12946-sec-0008}
=======

A total of 4323 lung cancer patients were included for analysis and 255 were excluded (our in‐house pathologist confirmed no lung cancer in 168 patients, incomplete medical treatment records for 43 patients, incomplete lung cancer staging for 36 patients, and secondary pulmonary malignancy in 8 patients). The recruitment flow process is presented in the supplemental material.

Demography {#tca12946-sec-0009}
----------

Age, gender, smoking status, cancer histology, cancer stage, and the treatment received were not statistically significantly different between the CKD and non‐CKD groups using either the CKD‐CG or CKD‐EPI formulas (Table [1](#tca12946-tbl-0001){ref-type="table"}). CKD patients presented with higher CCI scores compared to non‐CKD patients, regardless of the formula used (CKD‐CG 8 vs. 7, *P* = 0.007 and CKD‐EPI 9 vs. 8, *P* = 0.03). Table [2](#tca12946-tbl-0002){ref-type="table"} summarizes the cancer histology types according to clinical cancer stage.

###### 

Demographic characteristics of patients with CKD and non‐CKD based on CKD‐CG or CKD‐EPI formula

                                        CKD‐CG                                                     CKD‐EPI                                     
  --------------------------------- --------------- --------------- --------------- ---------- --------------- --------------- --------------- ----------
  Number of patients                  1668 (100)       834 (50)        834 (50)                  1666 (100)       833 (50)        833 (50)     
  Age (median + SD, years)             71 ± 9.42       71 ± 9.44       71 ± 9.40       0.08       75 ± 9.03       75 ± 8.87       75 ± 9.17       0.36
  Gender                                                                               0.76                                                       1.00
  Female                               551 (33)       272 (32.6)      279 (33.5)                 518 (31.1)      259 (31.1)      259 (31.1)    
  Male                                 1117 (67)      562 (67.4)      555 (66.5)                 1148 (68.9)     574 (68.9)      574 (68.9)    
  Smoking history                                                                      0.62                                                       0.46
  No                                  793 (47.5)      391 (46.9)      402 (48.2)                 748 (44.9)      366 (43.9)      382 (45.9)    
  Yes                                 875 (52.5)      443 (53.1)      432 (51.8)                 918 (55.1)      467 (56.1)      451 (54.1)    
  Creatinine (median + SD, mg/dL)     0.93 ± 0.96     0.79 ± 1.83     1.12 ± 1.25    \< 0.001    1.10 ± 1.12     0.86 ± 0.39     1.4 ± 1.38     \< 0.001
  eGFR (median + SD, mL/min)         59.99 ± 23.63   75.33 ± 18.30   48.73 ± 12.81   \< 0.001   59.95 ± 22.95   78.90 ± 12.95   47.40 ± 14.62   \< 0.001
  Comorbidity score (median + SD)      7 ± 2.53        7 ± 2.50        8 ± 2.56       0.007       9 ± 2.47        8 ± 2.50        9 ± 2.45        0.03
  Lung cancer stage                                                                     1                                                         0.31
  IA--IIIA                            377 (22.6)      188 (22.5)      189 (22.7)                 366 (22.0)      192 (23.0)      174 (20.9)    
  IA                                   71 (4.3)        34 (4.1)        37 (4.4)                   53 (3.2)        27 (3.2)        26 (3.1)     
  IB                                   94 (5.6)        48 (5.8)        46 (5.5)                   94 (5.6)        51 (6.1)        43 (5.2)     
  IIA                                  34 (2.0)        14 (1.7)        20 (2.4)                   29 (1.7)        16 (1.9)        13 (1.6)     
  IIB                                  29 (1.7)        17 (2.0)        12 (1.4)                   29 (1.7)        14 (1.71)       15 (1.8)     
  IIIA                                 149 (8.9)       75 (9.0)        74 (8.9)                   161 (9.7)       84 (10.1)       77 (9.2)     
  IIIB--IV                            1555 (77.4)     777 (77.3)      778 (77.4)                 1300 (78.0)     641 (77.0)      659 (79.1)    
  IIIB                                197 (11.8)      100 (12.0)       97 (11.6)                 184 (11.0)       90 (10.8)       94 (11.3)    
  IV                                  1094 (65.6)     546 (65.5)      548 (65.7)                 1116 (67.0)     551 (66.1)      565 (67.8)    
  Histology                                                                            0.80                                                       0.54
  NSCLC                               1512 (90.6)     758 (90.9)      754 (90.4)                 1479 (88.8)     744 (89.3)      735 (88.2)    
  SCLC                                 156 (9.4)       76 (9.1)        80 (9.6)                  187 (11.2)       89 (10.7)       98 (11.8)    
  Treatment                                                                            0.27                                                       0.40
  No treatment/supportive care        289 (17.3)      132 (15.8)      157 (18.8)                 421 (25.3)      200 (24.0)      221 (26.5)    
  Surgical treatment                  264 (15.8)      133 (15.9)      131 (15.7)                 210 (12.6)      111 (13.3)       99 (11.9)    
  OP                                   155 (9.3)       69 (8.3)        86 (10.3)                  126 (7.6)       64 (7.7)        64 (7.4)     
  OP + CT                              81 (4.9)        45 (5.4)        36 (4.3)                   67 (4.0)        38 (4.6)        29 (3.5)     
  OP + RT                               8 (0.5)         6 (0.7)         2 (0.2)                    6 (0.4)         2 (0.2)         4 (0.5)     
  OP + CT + RT                         10 (0.6)          8 (1)          2 (0.2)                    4 (0.2)         3 (0.4)         1 (0.1)     
  OP + Target                           9 (0.5)         3 (0.4)         6 (0.7)                    5 (0.3)         1 (0.1)         4 (0.5)     
  Medical treatment                   1115 (66.8)     569 (68.2)      546 (65.5)                 1035 (62.1)     522 (62.7)      513 (61.6)    
  CT                                  538 (32.3)      277 (33.2)      261 (31.3)                 481 (28.9)      232 (27.94)     249 (29.9)    
  CT + RT                             204 (12.2)      101 (13.2)       94 (11.3)                 172 (10.3)       94 (11.3)       78 (9.4)     
  CT + Target                          35 (2.1)        20 (2.4)        15 (1.8)                   41 (2.5)        23 (2.8)        18 (2.2)     
  RT                                   85 (5.1)        49 (5.9)        36 (4.3)                   98 (5.9)        57 (6.8)        41 (4.9)     
  RT + Target                          36 (1.7)        14 (1.8)        22 (2.6)                   34 (2.0)        15 (1.8)        19 (2.3)     
  Target                              215 (12.9)       98 (11.8)      117 (14.0)                 210 (12.6)      103 (12.4)      107 (12.8)    
  Cryotherapy                           2 (0.1)         2 (0.2)          0 (0)                     1 (0.1)         1 (0.1)          0 (0)      

CKD, chronic kidney disease; CKD‐CG, CKD‐Cockcroft--Gault formula; CKD‐EPI, CKD‐Epidemiology Collaboration formula; CT, chemotherapy; NSCLC, non‐small cell lung cancer; Op, surgical resection; RT, radiotherapy; SCLC, small cell lung cancer; Target, targeted therapy.

###### 

Cancer histology distribution according to cancer stage

  Histology type                  CKD‐CG (*n*, %)   CKD‐EPI (*n,* %)                                                                                                                                                                    
  ------------------------------ ----------------- ------------------ ----------- ---------- ----------- ---------- ----------- ----------- ------------ ------------ ------------ ------------ ------------ ------------ ------------- -------------
  NSCLC                              70 (98.6)          53 (100)       93 (98.9)   94 (100)   32 (94.1)   29 (100)   28 (96.6)   28 (96.6)   135 (90.6)   146 (90.7)   172 (87.3)   150 (81.5)   982 (89.8)   979 (87.7)   1512 (90.6)   1479 (88.8)
  Adenocarcinoma                        53                 35             53          43         14          13         15          13           62           61           59           46          659          608       915 (54.9)    819 (49.2)
  Squamous cell carcinoma               11                 14             27          33         12          12          9          12           48           67           80           79          189          212       376 (22.5)    426 (25.6)
  Adenosquamous cell carcinoma           1                 1               8          7           3          1           1           1           7            4            8            7            22           26         50 (3)       48 (2.9)
  Large cell carcinoma                   1                 0               3          6           0          1           0           1           7            5            6            5            12           23        29 (1.7)      41 (2.5)
  Sarcomatoid carcinoma                  0                 1               1          3           0          0           1           0           4            3            2            1            14           17        22 (1.3)      26 (1.6)
  Carcinoid tumor                        2                 0               0          0           0          0           1           0           0            0            0            0            2            1          5 (0.3)       2 (0.1)
  Salivary gland tumors                  0                 0               0          0           0          0           0           0           1            0            1            0            1            0          3 (0.2)        0 (0)
  NSCLC NOS                              2                 2               1          2           3          2           1           1           6            6            16           12           83           90        112 (6.7)     115 (6.9)
  Other                                  0                 0               0          0           0          0           0           0           0            0            0            0            0            2             0          2 (0.1)
  SCLC                                1 (1.4)            0 (0)          1 (1.1)     0 (0)      2 (5.9)     0 (0)      1 (3.4)     1 (3.4)     14 (9.4)     15 (9.3)    25 (12.7)    34 (18.5)    112 (10.2)   137 (12.3)    156 (9.4)    187 (11.2)

NSCLC, non‐small cell lung cancer; NOS, not otherwise specified; SCLC, small cell lung cancer.

Treatment {#tca12946-sec-0010}
---------

The proportion of patients who received supportive treatment was slightly higher in the CKD compared to the non‐CKD group (CKD‐CG 18.8% vs. 15.8% and CKD‐EPI 26.5% vs. 24%, respectively). The proportion of patients who received medical treatment was slightly higher in the non‐CKD compared to the CKD group measured by CKD‐CG (68.2% vs. 65.5%, respectively), while the proportion of patients who received surgical treatment was slightly higher in the non‐CKD compared to the CKD group measured by CKD‐EPI (13.3% vs. 11.9%, respectively) (Table [1](#tca12946-tbl-0001){ref-type="table"}).

Survival according to different chronic kidney disease (CK) formula {#tca12946-sec-0011}
-------------------------------------------------------------------

The OS rates were not statistically significantly different between the CKD and non‐CKD groups using either the CKD‐CG or the CKD‐EPI formula. Using the CKD‐CG formula, OS in the non‐CKD group was 10.61 months (95% CI 9.33--11.89) and 10.58 months (95% CI 9.03--12.13) in the CKD group (*P* = 0.76) (Fig [1](#tca12946-fig-0001){ref-type="fig"}a). Using the CKD‐EPI formula, OS in the non‐CKD group was 9.10 months (95% CI 8.01--10.20) and 7.59 months (95% CI 6.50--8.68) in the CKD group (*P* = 0.19) (Fig [1](#tca12946-fig-0001){ref-type="fig"}b).

![Survival curves of lung cancer with and without chronic kidney disease (CKD) according to the (**a**) CKD‐Cockcroft--Gault (CKD‐CG) and (**b**) CKD‐Epidemiology Collaboration formulas. (![](TCA-10-268-g004.jpg "image")) CKD (−), (![](TCA-10-268-g002.jpg "image")) CKD (+), (![](TCA-10-268-g003.jpg "image")) CKD (−)‐censored, and (![](TCA-10-268-g005.jpg "image")) CKD (+)‐censored.](TCA-10-268-g001){#tca12946-fig-0001}

Non‐CKD versus CKD survival {#tca12946-sec-0012}
---------------------------

Age, gender, smoking status, cancer histology, cancer stage, and treatment received were not statistically different between the CKD and non‐CKD groups according to either the CKD‐CG or CKD‐EPI formulas (Table [3](#tca12946-tbl-0003){ref-type="table"}). The survival rates by cancer stage of patients with and without CKD and according to the different CKD stages are presented in Table [4](#tca12946-tbl-0004){ref-type="table"}. Survival rates according to the different CKD stages in cancer stages IIIB--IV were statistically significantly different using the CKD‐CG (*P* = 0.004) and CKD‐EPI formulas (*P* \< 0.001). However, survival in cancer stage IA--IIIA patients was statistically different using the CKD‐CG formula (*P* \< 0.001) and only marginally significant using the CKD‐EPI formula (*P* = 0.054).

###### 

Kaplan--Meier survival analysis of non‐CKD and CKD groups using the CKD‐CG and CKD‐EPI formulas

  Characteristics      CKC‐CG     CKD‐EPI                                                                                 
  ------------------- -------- -------------- ------- -------------- ------ ------- -------------- ------- -------------- ------
  Overall survival     10.61    9.33--11.89    10.58   9.03--12.13    0.76   9.10     8.01--1.20    7.59     6.50--8.68    0.19
  Age                                                                 0.78                                                 0.17
  \< median value      12.39    10.29--14.48   14.23   11.94--16.51   0.73   11.14   9.46--13.34    10.71   8.92--12.51    0.79
  \> median value       9.10     7.17--1103    7.95     6.49--9.42    0.46   6.11     4.52--7.71    4.90     3.84--5.95    0.10
  Gender                                                              0.76                                                 0.21
  Female               13.50    10.61--16.39   15.11   11.70--18.52   0.39   13.73   11.23--16.24   9.23    6.77--11.69    0.66
  Male                  9.27    7.80--10.73    9.53    8.28--10.78    0.33   7.52     6.09--8.96    6.67     5.39--7.95    0.23
  Smoking history                                                     0.70                                                 0.26
  No                   14.03    11.48--16.58   14.88   11.91--17.86   0.74   12.09   9.86--14.33    8.64    6.42--10.86    0.50
  Yes                   8.87    7.50--10.24    9.00    7.76--10.25    0.40   7.33     5.87--8.78    6.77     5.60--7.94    0.37
  Comorbidity score                                                   0.68                                                 0.63
  \< median value      14.52    11.87--17.17   16.07   13.01--19.12   0.45   10.32   8.88--11.75    9.76    7.84--11.68    0.74
  \> median value       6.87     5.41--8.33    6.97     5.68--8.25    0.89   5.29     3.39--7.19    4.40     2.88--5.73    0.67
  Stage                                                               0.97                                                 0.29
  IA--IIIA             41.23    33.55--49.31   35.15   20.42--49.89   0.27   30.82   21.77--39.87   24.38   17.61--31.14   0.71
  IIIB--IV              7.82     6.61--9.03    8.02     6.86--9.17    0.66   6.37     5.19--7.56    5.59     4.69--6.48    0.32
  Histology                                                           0.81                                                 0.28
  NSCLC                11.37    9.72--13.02    11.17   9.32--13.03    0.86   9.96    8.74--11.17    8.51     7.19--4.78    0.26
  SCLC                  6.21     4.41--8.01    5.75     3.27--8.23    0.82   4.70     3.97--5.42    3.29     1.79--4.73    0.91
  Treatment                                                           0.96                                                 0.15
  Supportive            2.73     1.15--4.30    2.40     1.47--3.33    0.59   2.79     2.18--3.41    1.64     1.02--2.26    0.04
  Medical               9.13    7.85--10.42    10.02   8.54--11.50    0.66   9.43    8.32--10.54    8.64    7.14--10.14    0.57
  Surgical             70.57    55.90--85.25   61.83   49.97--73.70   0.77   48.82   31.90--65.75   60.35   51.71--68.99   0.86

Overall survival was not statistically significantly different between the CKD and non‐CKD groups using either the chronic kidney disease Cockcroft--Gault (CKD‐CG) or CKD‐Epidemiology Collaboration (CKD‐EPI) formulas. CI, confidence interval; NSCLC, non‐small cell lung cancer; SCLC, small cell lung cancer.

###### 

Survival by cancer stage according to the presence or absence of CKD and CKD stage

  Cancer stage    Formula         Non‐CKD                 CKD 3A                CKD 3 B                 CKD 4                  CKD 5                  *P*                                                                                                   
  -------------- --------- ---------------------- ---------------------- ---------------------- ---------------------- --------------------- ---------------------- --------------------- --------------------- --------------------- --------------------- ---------
  IA--IIIA        CKD‐CG            188            41.43 (33.55--49.31)           120            48.72 (30.42--67.03)           48            27.40 (12.36--42.44)           13            14.88 (0.00--34.91)            8            10.22 (0.00--32.57)    0.004
  CKD‐EPI           192     30.82 (21.77--39.87)           102            27.83 (11.40--44.25)            37            19.45 (8.17--30.73)            20            42.35 (8.06--76.64)           15            10.22 (0.00--22.26)          0.054         
  IIIB--IV        CKD‐CG            646             7.82 (6.61--9.03)             397            10.25 (8.53--11.97)            169            6.21 (4.55--7.87)             47             3.75 (2.99--4.50)            32             3.35 (0.54--6.16)    \<0.001
  CKD‐EPI           641      6.37 (5.19--7.56)             366             6.77 (5.17--8.37)             162             4.01 (3.15--4.87)             83             4.57(3.02--6.11)             48             3.35 (0.00--6.72)          \<0.001        

The survival differences using the chronic kidney disease‐Epidemiology Collaboration (CKD‐EPI) formula were significant for cancer stage IIIB--IV (*P* \< 0.001) but not for IA--IIIA (*P* = 0.054). CKD stage 3A (estimated glomerular filtration rate \[eGFR\] range 45--60 mL/min/1.73 m^2^). CKD stage 3B (eGFR range 30--45 mL/min/1.73 m^2^). CKD stage 4 (eGFR range 15--30 mL/min/1.73 m^2^). CDK stage 5 (eGFR \<15 mL/min/1.73 m^2^). CI, confidence interval; CKD‐CG, CKD‐ Cockcroft--Gault.

In the adjusted Cox proportional hazard analysis model, age, CCI score, cancer stage, cancer histology, and treatment mode were factors associated with increased mortality when measured by both formulas. Male patients had an increased risk of death when measured using the CKD‐EPI formula (hazard ratio \[HR\] 1.24, 95% CI 1.07--1.43; *P* = 0.01) but the result did not reach statistical significance using the CKD‐CG formula. Using an eGFR \< 60 mL/minute/1.73 m^2^ as an indicator of CKD, CKD patients presented with decreased survival when measured using the CKD‐CG formula (HR 0.96, 95% CI 0.88--1.08; *P* = 0.65) and an increased risk of death when measured using the CKD‐EPI formula (HR 1.05, 95% CI 0.95--1.17; *P* = 0.33), but these results did not reach statistical significance. With medical treatment as the reference, patients receiving supportive treatment had an increased risk of death according to both formulas, while those receiving surgical treatment had a decreased risk of death (Table [5](#tca12946-tbl-0005){ref-type="table"}).

###### 

Adjusted Cox proportional hazard analysis for CKD group based on CKD‐CG and CKD‐EPI formulas

                       CKD‐CG                           CKD‐EPI               
  ------------------- -------- ------------ ---------- --------- ------------ ----------
  Age                   1.02    1.01--1.02   \< 0.001    1.02     1.02--1.03   \< 0.001
  Gender                                                                      
  Female                Ref                               Ref                 
  Male                  1.11    0.96--1.28     0.18      1.24     1.07--1.43    0.004
  Comorbidity score     1.06    1.04--1.09   \< 0.001    1.06     1.04--1.08   \< 0.001
  Smoking history                                                             
  No                    Ref                               Ref                 
  Yes                   1.15    1.00--1.33     0.05      1.12     0.98--1.28     0.11
  CKD status                                                                  
  No                    Ref                               Ref                 
  Yes                   0.96    0.88--1.08     0.65      1.05     0.95--1.17     0.33
  Stage                                                                       
  IA--IIIA              Ref                               Ref                 
  IIIB--IV              1.73    1.45--2.07   \< 0.001    1.81     1.52--2.16   \< 0.001
  Histology                                                                   
  NSCLC                 Ref                               Ref                 
  SCLC                  1.59    1.33--1.90   \< 0.001    1.76     1.49--2.07   \< 0.001
  Treatment                                                                   
  Supportive            1.96    1.71--2.25   \< 0.001    2.00     1.77--2.25   \< 0.001
  Medical               Ref                               Ref                 
  Surgical              0.37    0.29--0.47   \< 0.001    0.45     0.35--0.57   \< 0.001

Using the chronic kidney disease Cockcroft--Gault (CKD‐CG) formula, lung cancer patients with CKD showed a 4% decrease in survival and a 5% increased risk of death using the CKD‐Epidemiology Collaboration (CKD‐EPI) formula. CKD is not an independent predictor for lung cancer survival regardless of the formula used to estimation the glomerular filtration rate. Younger patients, women, lower comorbidity scores, cancer stages I--IIIA, and surgical treatment were associated with improved survival. HR, hazard ratio; NSCLC, non‐small cell lung cancer; SCLC, small cell lung cancer.

Discussion {#tca12946-sec-0013}
==========

Patients with cancer are usually older in general, with a higher prevalence of comorbidities, such as CKD. The prevalence of CKD is high in the elderly, affecting \> 40% of people over the age of 70 years.[16](#tca12946-bib-0016){ref-type="ref"} According to the National Health and Nutrition Examination Survey (NHANES) study 1988--1994 and the 1999--2004 NHANES study, the prevalence of CKD increased from 5.4% to 7.7% over this period.[17](#tca12946-bib-0017){ref-type="ref"} In clinical practice, an eGFR \< 60 mL/minutes/1.73 m^2^ serves as an indicator of CKD. However, using a different formula to calculate the eGFR may classify these patients differently. Using the CKD‐CG formula, 38.3% of patients had CKD in this study, but only 21.7% when using the CKD‐EPI formula. The coexistence of lung cancer and CKD is reported at approximately 13%.[4](#tca12946-bib-0004){ref-type="ref"}, [5](#tca12946-bib-0005){ref-type="ref"} In this study, we observed a higher proportion of CKD patients, which could be related to the high incidence and prevalence of CKD in southern Taiwan (513/million and 3297/million, respectively).[18](#tca12946-bib-0018){ref-type="ref"}

The overall prognosis for lung cancer is dismal, with a five‐year relative survival rate of only 19.9%.[19](#tca12946-bib-0019){ref-type="ref"} In a small retrospective study of 107 patients, Patel *et al*. reported similar survival rates for CKD and non‐CKD lung cancer patients using an eGFR of ≤ 90 mL/minute/1.73 m^2^ to define CKD[6](#tca12946-bib-0006){ref-type="ref"} We believe that the CKD patient sample used by Patel *et al*. with a mean eGFR of 71 mL/min/1.73 m^2^ had a renal function that is too good to be considered CKD patients. In a previous retrospective report using the CG formula, Lu *et al*. found similar rates of survival between CKD and non‐CKD patients.[8](#tca12946-bib-0008){ref-type="ref"} Xie *et al*. recommended using the CKD‐EPI formula for Chinese patients to detect CKD based on the correlation, precision, limit of agreement, and simplicity compared to other formulas.[20](#tca12946-bib-0020){ref-type="ref"} We used two formulas to evaluate the effect of different GFR estimations on lung cancer survival. Using the CKD‐CG formula, the median survival of non‐CKD patients was 10.61 months (95% CI 9.33--11.89) compared to 10.58 months (95% CI 9.03--12.13) in the CKD group (*P* = 0.76); while the median survival was 9.10 months (95% CI 8.01--10.20) for the non‐CKD group compared to 7.59 months (95% CI 6.50--8.68) for the CKD group (*P* = 0.19) when using the CKD‐EPI formula. We conclude that the survival rates in CKD and non‐CKD patients did not differ significantly using either formula.

Lung cancer is most frequently diagnosed among people aged 65--74, with a median age at diagnosis of 70 years, according to the Surveillance, Epidemiology, and End Results Cancer Statistics Review, 1975--2015.[19](#tca12946-bib-0019){ref-type="ref"} In the present report, the median age at diagnosis was 71 using the CKD‐CG formula and 75 using the CKD‐EPI formula. We found that older patients had higher mortality rates, with a HR of 1.02 using the CKD‐CG and CKD‐EPI formulas (Table [5](#tca12946-tbl-0005){ref-type="table"}). Older patients were more inclined to choose no treatment/supportive treatment, more significantly deviating from treatment protocol because of intolerance to side effects, and a lack of suitability for radical surgical resection, which could result in the inferior survival rates compared to younger patients. Kale *et al*. reported four‐fold to six‐fold increases in toxicity related to chemoradiation therapy in elderly patients with advanced stage lung cancers[21](#tca12946-bib-0021){ref-type="ref"} however, the survival rates of elderly patients (\> 75 years) after radical treatment did not differ significantly from those of younger patients.[22](#tca12946-bib-0022){ref-type="ref"}

Several studies have reported gender differences in lung cancer survival.[23](#tca12946-bib-0023){ref-type="ref"}, [24](#tca12946-bib-0024){ref-type="ref"}, [25](#tca12946-bib-0025){ref-type="ref"} According to Wisnivesky *et al*., women have better lung cancer‐specific, overall, and relative survival than men in all treatment groups.[24](#tca12946-bib-0024){ref-type="ref"} The gender‐related differences in cancer affecting both sexes are more prominent in lung cancer at localized, regional, and unknown stages.[26](#tca12946-bib-0026){ref-type="ref"} Sagerup *et al*. reported that regardless of stage, age, the period of diagnosis, and selected histological subgroups, men had an increased risk of death at five‐years.[27](#tca12946-bib-0027){ref-type="ref"} According to recent cancer statistics in the United States, the five‐year relative survival by gender for all races was 21.5% for women and 15.4% for men.[2](#tca12946-bib-0002){ref-type="ref"} Analysis of our data revealed different gender‐difference outcomes using the CKD‐CG and CKD‐EPI formulas. Using the CKD‐CG formula, men had an 11% higher risk of death (HR 1.11, 95% CI 0.96--1.28; *P* = 0.18) than women and the increased risk of death was 24% according to the CKD‐EPI formula (HR 1.24, 1.07--1.43; *P* = 0.01) (Table [5](#tca12946-tbl-0005){ref-type="table"}). This difference in gender‐related survival deserves further investigation.

Patients usually present at advanced stages of lung cancer at the time of diagnosis. In this report, survival rates by cancer stage between CKD and non‐CKD patients according to either formula did not differ significantly (Table [3](#tca12946-tbl-0003){ref-type="table"}). The survival rates by cancer stage (stage I--IIIA and IIIB--IV) for the different stages of renal impairment (non‐CKD, CKD 3A, CKD 3B, CDK 4, and CKD 5) were different according to the formula used to estimate GRF. Using the CKD‐CG formula, the survival differences were statistically significant for cancer stages I--IIIA and IIIB--IV. However, using the CKD‐EPI formula, the survival differences were significant for cancer stage IIIB--IV (*P* \< 0.001), but not for IA--IIIA (*P* = 0.054) (Table [4](#tca12946-tbl-0004){ref-type="table"}). Because the survival rate estimated for patients with cancer I--IIIA/CKD stage 4 via the CKD‐EPI formula was significantly higher (median survival 42.35 vs. CKD‐CG 14.88 months), this may have affected the statistical results. The survival rate did not differ significantly between CKD and non‐CKD groups based on the type of treatment administered (medical or surgical) when using either formula. However, the survival rate for CKD patients was significantly lower when using CKD‐EPI formula (*P* = 0.04) (Table [3](#tca12946-tbl-0003){ref-type="table"}).

While surgical resection is recommended for early‐stage lung cancer and offers the best prospect of cure, physical fitness and medical comorbidities may prevent early‐stage patients from undergoing surgical resection. The presence of comorbidities frequently influences the treatment selection for lung cancer patients. Iachina *et al*. evaluated the effect of different comorbidities on lung cancer survival.[28](#tca12946-bib-0028){ref-type="ref"} They found that cardiovascular disease, diabetes, cerebrovascular disorders, and chronic obstructive pulmonary disease have a significant impact on survival in NSCLC patients. Unfortunately, because renal disease and other comorbidities were grouped together, the independent effect of CKD was not evaluated.[27](#tca12946-bib-0027){ref-type="ref"} In this report, we summed each of the independent morbidity scores to a total score and graded them according to the median. Although OS rates in the CKD and non‐CKD groups were not statistically significantly different using either formula, we found a consistently increased risk of mortality in Cox proportional hazard analysis (Table [5](#tca12946-tbl-0005){ref-type="table"}).

Results of the interface between lung cancer mortality outcome and the coexistence of CKD are conflicting. Na *et al*. reported that an eGFR of \< 60 mL/minutes is associated with a 12% increase in the overall mortality rate for several types of cancer, but not lung cancer, independent of other known risk factors.[4](#tca12946-bib-0004){ref-type="ref"} Lu *et al*. found a 6% increased risk of death for CKD patients; however, this result was not statistically significant (HR 1.06, 95% CI 0.93--1.22; *P* = 0.41).[8](#tca12946-bib-0008){ref-type="ref"} In a recent population‐based cohort study in Taiwan of lung cancer patients with coexisting CKD, Wei *et al*. found that CKD increased the mortality risk by 38%.[7](#tca12946-bib-0007){ref-type="ref"} The authors used specific International Classification of Disease codes to determine CKD and included mostly CKD stage 5 patients.[7](#tca12946-bib-0007){ref-type="ref"} In this study, the CKD‐CG showed a 4% decrease in survival in lung cancer patients with CKD (HR 0.96, 95% 0.88--1.08; *P* = 0.65) while the CKD‐EPI showed a 5% increased risk of death (HR 1.05, 95% CI 0.95--1.17; *P* = 0.33) (Table [5](#tca12946-tbl-0005){ref-type="table"}). CKD was not an independent predictor of lung cancer survival, regardless of the formula used to estimate GFR.

The retrospective design of this study, the absence of standardized and possible overlapping treatments, and the somewhat small number of patients may have influenced the survival outcomes reported and are the major limitations of this report. We caution extrapolation of the same conclusion in other populations because of the high incidence of CKD in our cohort.

In our limited experience of Taiwanese patients, CKD with an eGFR \< 60 mL/minute/1.73 m^2^ is not an independent risk factor for lung cancer survival. Lung cancer survival did not differ significantly between CKD and non‐CKD patients either using the CKD‐EPI or CKD‐CG formulas. Patients with good physical performance should be administered radical treatment.
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